產品
CRISPR Therapeutics presents Phase 1a CTX310 data at ESC Congress 2026
CRISPR Therapeutics presented Phase 1a data for CTX310, its in vivo ANGPTL3 gene-editing candidate, at ESC Congress 2026. The company describes deep and durable ANGPTL3 editing with triglyceride and LDL lowering. Specific percentage reductions are in the release but are not restated here.
大盤 開啟原文 ↗